Saint-Gobain Life Sciences has announced the acquisition of MS Techniques and sister company Transluminal. The company brings to Saint-Gobain more than a quarter century of thermoplastic extrusion and design expertise applied to minimally invasive catheter systems, specifically for the cardio-vascular market.

Located in Pompey, France, near Nancy, MS Techniques/Transluminal employs 137 people. Its design and manufacturing capabilities will be complemented by Saint-Gobain’s material expertise, financial strength, and global presence in the medical device market, said the press release. MS Techniques and Transluminal will be integrated within Saint-Gobain Life Sciences’ Medical Components business unit. 

“We are looking forward to welcoming MS Techniques and Transluminal to the Saint-Gobain Medical family,” said John Schmitz, General Manager, Saint-Gobain’s Medical Components and Electronics. “Aligning with our growth strategy, they strengthen our presence in Europe, broaden our precision extrusion capabilities and catheter design expertise, helping us further expand into the interventional and minimally invasive market.”

MS Techniques and Transluminal have a strong track record of developing catheter technologies that fit the needs of their customers. Saint-Gobain said that it will focus on preserving, supporting, and further investing in the company’s rich culture of innovation. 

“We decided to join forces with Saint-Gobain because we felt we found a true partnership and shared the same vision — to become a world-class reference in the medical device industry for delivering minimally invasive innovation,” said MS Techniques President Etienne Malher. “Joining a global medical organization with the size and tremendous legacy of Saint-Gobain makes it possible to carry forward what we have worked so hard to build over the last 28 years. With more resources and the Saint-Gobain brand supporting our efforts, we pave the way for future innovation and the co-development of new medical solutions with our customers,” added Malher.

Saint-Gobain Life Sciences has its US base in Solon, OH, and is part of the Saint Gobain group headquartered at La Défense, "le petit Manhattan" just outside of Paris. The group operates in 70 countries with more than 180,000 employees. It reported €42.6 billion in sales in 2019.